Annual Report 2003 Aventis - Sanofi

Targocid (teicoplanin) is a consistent and
reliable agent that targets the growing
problem of hospital-based infections.
Approved indications
Potentially serious infections caused
by susceptible Gram-positive bacteria,
including those resistant to other antibiotics
such as penicillins and cephalosporins.
Major markets
Targocid is available throughout Europe,
Asia and Latin America. Aventis does not
sell this product in the U.S.
Product features
- Targocid is useful in the therapy of
serious staphylococcal infections in
patients who cannot receive or who have
failed to respond to the penicillins and
cephalosporins, or who have infections
with staphylococci resistant to other
antibiotics
- Effective in range of infections, including
skin and soft tissue infections,
urinary tract infections, lower respiratory
tract infections, joint and bone infections
and septicaemia
>> 41